Novartis: Pipeline Progress And Buyback Drive Upside

Group 1 - The coverage of Novartis is being resumed after a summer break, indicating renewed interest in the company [1] - A 39% duty on Swiss goods was enacted by Trump in early August, but pharmaceuticals are exempt due to the USA's reliance on Swiss pharmaceutical products [1] Group 2 - The article expresses a beneficial long position in Novartis shares, indicating confidence in the company's future performance [2]